“We work systematically to strengthen our core business by delivering growth through the introduction of new products in existing markets and expanding products to new geographies. We have started and will continue the tedious process to increase company value by owning new products and brands. As a third step, we have been and will actively continue to source and evaluate M&A opportunities to deliver sustainable growth with the objective of building Navamedic to a leading Nordic pharmaceutical company with a footprint in North Europe and other selected countries,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
Stock exchange news
Financial calendar for Navamedic ASA FINANCIAL YEAR 2020 18.02.2021 – Quarterly Presentation - Q4 30.04.2021 – Annual Report Read more
Navamedic ASA: Q3 2020 financial results
“In the third quarter of 2020, we delivered strong growth driven by both the addition of new products such as Read more
Navamedic ASA: Invitation to 2020 third quarter presentation
Navamedic ASA invites you to a presentation of the 2020 third quarter figures on Friday November 6th at 08.30 CET. Read more
Meet us at exhibitions and fairs
Unfortunately, due to Covid-19. Exhibitions are postponed or cancelled until further notice.